common, as only a subset of CTCF sites form insulated neighborhoods (8, 10, 24) . CTCF cohesinbound loops are largely preserved across cell types (8, 9, 24) , and a set of~10,000 constitutive CTCF-CTCF loops shared by GM12878 lymphoblastoid, Jurkat, and K562 (CML) cells (24) were identified for comparison (Fig. 4A, fig. S11 , and table S8). We used the International Cancer Genome Consortium (ICGC) database-which contains data for~50 cancer types,~2300 whole-genome sequence (WGS) samples, and~13 million unique somatic mutations-to examine the boundaries of these neighborhoods for somatic point mutations found in cancer genomes (table S9) . We found a striking enrichment of mutations at the CTCF boundaries of constitutive neighborhoods (Fig. 4B, fig. S12A , and table S10) relative to regions flanking the boundary CTCF sites (±1 kb of the CTCF binding motif; P < 10 (table S10) , and recurrent mutations occurred more frequently in neighborhood boundary CTCF sites relative to nonboundary CTCF sites (fig. S16, A to C). The genes located within the most frequently mutated neighborhoods included known cellular proto-oncogenes annotated in the Cancer Gene Census and other genes that have not been associated with these cancers (Fig. 4 , E and F, and tables S11 and S12). Shown in Fig. 4 , G and H, are two examples of proto-oncogene-containing neighborhoods where the activation of the gene located in the neighborhood has been observed in the respective cancer type. These results suggest that somatic mutations of insulated neighborhood boundaries occur in the genomes of many different cancers.
Our findings indicate that disruption of insulated neighborhood boundaries can cause oncogene activation in cancer cells. With maps of 3D chromosome structure such as those described here, cancer genome analysis can consider how recurrent perturbations of boundary elements may affect the expression of genes with roles in tumor biology. Our understanding of 3D chromosome structure and its control is rapidly advancing and should be considered for potential diagnostic and therapeutic purposes. Because control of 3D chromosome structure involves binding of specific sites by CTCF and cohesin, which is affected by protein cofactors, DNA methylation, and local RNA synthesis (25) , advances in our understanding of these regulatory processes may provide new approaches to therapeutics that have an impact on aberrant chromosome structures. Germline targeting, a vaccine priming strategy to initiate the affinity maturation of select germline-precursor B cells, has promise to initiate bnAb induction. The goals for a germline-targeting prime are to activate B cell precursors with bnAb potential, select productive (bnAb-like) somatic mutations, and generate an expanded population of memory B cells that can be boosted and matured subsequently to shepherd the response further toward bnAb development (2, 3) . For a few HIV bnAbs, next-generation sequencing of antibody populations during bnAb development in infected individuals has allowed bioinformatic inference of likely human germline precursors (4, 5) . For most bnAbs, however, true human precursors are not known but are usually approximated by "germline-reverted" antibodies that use inferred germline V and J genes and retain mature CDR3 (complementarity-determining region 3) loops. Because CDR3 loops typically play a major role in antibody affinity and specificity, germlinereverted bnAbs are not known to be reliable proxies for true germline precursors.
HIV-1 VACCINES
VRC01-class bnAbs are an important test case for germline targeting, because they are among the most broad and potent of HIV bnAbs and because their germline-reverted forms show no detectable affinity for HIV Env glycoproteins (6) (7) (8) (9) (10) . Knock-in mice transgenic for a germline-reverted VRC01-class heavy chain responded to immunization with the germline-targeting eOD-GT8 60-subunit self-assembling nanoparticle (60mer) but not with native-like Env trimers, providing proof of principle that germline-targeting immunogens can initiate a VRC01-class response if well-matched B cells are present and competing B cells are strongly reduced in frequency (2, 3) . Here, we address further critical knowledge gaps that obstruct the development of this (or any) germlinetargeting immunogen as a human vaccine: Do the targeted bnAb precursors exist in humans? What is the frequency and person-to-person variation of germline-targeting immunogen-specific bnAb precursors? Can the germline-targeting immunogen bind the targeted human bnAb precursors in competition with other B cells in the fully complex human B cell repertoire? We examined these questions by developing new ex vivo approaches and protein design methods.
When we used the VRC01-class germlinetargeting immunogen eOD-GT6 (9) as bait to screen human naïve B cells via a two-phase multiple-validation methodology (11) (fig. S1 ), we failed to isolate VRC01-class B cells. We did, however, isolate non-VRC01-class naïve B cells with Ab affinities as low as 120 mM for eOD-GT6 ( fig. S1 ). We therefore set out to develop an improved variant of eOD-GT6 with higher affinity and breadth for germline-reverted VRC01-class Abs, hypothesizing that such improvements might translate into improved affinity for diverse true VRC01-class precursor Abs.
To improve on eOD-GT6, we used yeast display library screening coupled with next-generation sequencing (12) . We screened a library of every point mutation at the 58 eOD:Ab interface positions on eOD-GT7, a slightly improved version of eOD-GT6 (11), against each of 29 VRC01-class Abs (18 germline-reverted and 11 mature bnAbs). By measuring binding enrichments for each mutation and antibody ( Fig. 1A and fig. S2 ), we identified 12 positions in eOD-GT7 at which one or more mutations were favorable (enriched by at least a factor of 2) for binding to the majority (at least 10 of 18) of germline-reverted bnAbs, and another four positions at which one or more mutations were enriched by at least a factor of 1.25 for binding to the vast majority (at least 17 of 18) of germline-reverted bnAbs (Fig. 1B) . To identify combinations of mutations predicted to confer the greatest binding cross-reactivity, we then created a library encompassing all combinations of a filtered set of the favorable mutations at those 16 positions (13) (Fig. 1C) . Upon screening this combinatorial library against the panel of 29 VRC01-class Abs, we identified a sequence, eOD-GT8, predicted to have optimal breadth against the entire panel (Fig. 1C , figs. S3 and S4, and table S1).
Relative to eOD-GT6, eOD-GT8 demonstrated superior affinity and breadth of binding to germline-reverted Abs ( Fig. 1D and table S2 ). eOD-GT8 bound to all germline-reverted Abs in the panel, whereas eOD-GT6 bound to only 8 of 14 Abs with dissociation constants (K D ) of less than 100 mM. For those eight germline-reverted Abs, the geometric mean affinity of eOD-GT8 was higher than that of eOD-GT6 by a factor of 2100; eOD-GT8 also had improved affinity (factor of 3) for VRC01-class bnAbs. The tightest eOD-GT8 binding detected was for germline-reverted PGV20, with a K D of 508 fM (95% confidence interval, 234 to 943 fM) (Fig. 1D and fig. S5 ), a factor of 5900 improvement over eOD-GT6 (K D = 3 nM) and a factor of 33 million improvement over the original eOD construct, eOD Base [K D = 17 mM (9)]-a remarkable affinity improvement for a protein-protein interface.
To examine whether VRC01-class precursors targeted by eOD-GT8 exist in humans, we performed epitope-specific B cell sorting from a pool of peripheral blood mononuclear cells from healthy, HIV-seronegative donors. Epitope-specific B cells bound tetramers of eOD-GT8 but not tetramers of eOD-GT8-KO, a variant of eOD-GT8 with mutations abrogating binding by VRC01-class germlinereverted Abs. After sequencing immunoglobulin (Ig) genes from single sorted cells, we searched for VRC01-class antibody sequences-that is, those with a heavy chain that used VH1-2 alleles *02, *03, or *04 and a light chain with a 5-amino acid CDR3 (9, 14 S6 ).
To assess both the percentage of people who possess VRC01-class germline precursor B cells and the frequency of VRC01-class germline precursor B cells within a given donor, we screened naïve B cells from 15 healthy, HIV-seronegative donors individually rather than pooled. For 7 of 15 samples, we used the two-phase multiplevalidation methodology that first assesses specificity by probe binding in flow cytometry and then confirms specificity and lack of polyreactivity by single-cell secreted IgM (fig. S7); for eight subsequent donors, we relied on sorting specificity alone. For optimal cell sorting sensitivity, B cells were required to simultaneously bind two eOD-GT8 probes multimerized differently [trimer ("tri") and streptavidin tetramers ("SA")] while not binding eOD-GT8-KO-SA ( Fig. 2A and fig. S7 ). For the 15 donors, the mean frequency of eOD-GT8 tri+/SA+ B cells among 61.6 million naïve B cells sorted was 0.0056% (Fig. 2B) . Strikingly, a vast majority (84 ± 14%) of these eOD-GT8 tri+/SA+ B cells did not bind eOD-GT8-KO-SA (Fig. 2C) , which suggests that naïve B cell reactivity to eOD-GT8 is highly focused to the CD4 binding site (CD4bs) (15) .
Paired heavy and kappa light chain sequences were recovered from 173 eOD-GT8 tri+/SA+ /eOD-GT8-KO -B cells. All sequences were essentially germline, confirming the naïve B cell sorts. Half (50%) of these B cells were VH1-2, whereas only 4% of control B cells from reference (16) were VH1-2 (c 2 = 29.9, P < 0.0001; Fig. 2D and fig. S8 ). Among these 87 VH1-2 + B cells, 26 had a light chain CDR3 (L-CDR3) length of 5 amino acids, a factor of 85 enrichment relative to control B cells (c 2 = 32.6, P < 0.0001; Fig. 2E ). Twenty-five of the 26 used the VH1-2*02 allele and one used VH1-2*04 (table S3) we identified 27 independent VRC01-class naïve B cells, including VRC01c-HuGL1. In addition to the VH1-2 alleles and critical 5-amino acid L-CDR3, VRC01-class bnAbs possess several additional defining features, including a consensus L-CDR3 of Gln-Gln-Tyr-Glu-Phe (QQYEF). The majority of VRC01-class precursors we isolated contained a QQYxx partial VRC01-class consensus motif that was significantly enriched relative to control B cells (67% versus 11%; c 2 = 8.2, P < 0.0001; Fig. 2F ). Furthermore, 11% contained a QQYEx L-CDR3 motif (versus 1.5% of control B cells), one mutation away from a perfect mature VRC01-class L-CDR3 (Fig. 2F) . In addition, the L-CDR1 loop is under strong selective SCIENCE sciencemag.org 25 MARCH 2016 • VOL 351 ISSUE 6280 pressure during VRC01-class bnAb affinity maturation to minimize clashes with gp120 (6, 17) . VRC01-class bnAb L-CDR1 loops generally become very short (2 to 6 amino acids) through deletion, or retain a germline length of 6 amino acids and add flexible glycines (17) . Of the 27 VRC01-class precursors isolated by eOD-GT8, 23 used Vk genes containing L-CDR1 loops of 6 or 7 amino acids (Fig. 2G) , thus confirming potential to develop into VRC01-class bnAbs. Indeed, 17 of the VRC01-class naïve B cells had Vk genes used in known VRC01-class bnAbs (Fig. 2H) . At least 24 of the VRC01-class precursors had H-CDR3 lengths of 10 to 19 amino acids (Fig. 2I) (18) , consistent with known VRC01-class bnAb lengths of 10 to 19 amino acids. Thus, not only are the eOD-GT8 isolated naïve B cells highly enriched for VRC01-class core characteristics of VH1-02 and a 5-amino acid L-CDR3, they possess further refined sequence attributes of VRC01-class bnAbs.
Combining data from the 15 donors analyzed individually, the overall frequency of recovered VRC01-class precursors was 1 in 2.4 million naïve B cells (Fig. 2J) , consistent with both our first pooled sort and a previous bioinformatically estimated range (17) . The observed counts were consistent with a Poisson distribution with constant frequency of 1 in 2.4 million (Fig. 2K) (11) , which suggests that VRC01-class precursors occur at a consistent rate among 96% of humans possessing the necessary VH1-2 alleles (9). Adults have an estimated 10 10 to 10 11 B cells, and lymph nodes each have~50 million B cells, of which~65 to 75% are naïve B cells (19) . Thus, our results indicate that VRC01-class precursor B cells are relatively common in humans: At least 2700 to 31,000 eOD-GT8-reactive VRC01-class naïve B cells are likely present in nearly all potential human vaccine recipients, with~15 such B cells in each lymph node, at any given time (20) .
The K D values of 24 isolated VRC01-class precursors for monovalent eOD-GT8 ranged from 57 mM to 125 nM, with a geometric mean K D of 3.4 mM (Fig. 2L and table S4 ), weaker than germline-reverted VRC01-class Abs by a factor of Fig. 1 . Development of eOD-GT8. (A) Model of germlinereverted VRC01 (gray surface) interacting with eOD-GT7 (cartoon) with the 58 positions subjected to deep mutational scanning shown as magenta, green, and orange spheres representing the three mutagenized linear segments. Binding enrichments, the ratio of the frequency of a mutation in the top 10% binding population to the frequency of the same mutation in all cells displaying eOD-GT7, were computed for each mutation on eOD-GT7 for germlinereverted VRC01 and are shown as a heat map on the right, in which blue denotes unfavorable mutations, red denotes favorable mutations, and white denotes the amino acid residue in eOD-GT7. (B) The combined binding enrichments from independent yeast display screens for 18 germline-reverted VRC01-class bnAbs are shown as a multidimensional heat map in which the color scale from yellow to red indicates increasing favorable average enrichment. Symbol sizes reflect the breadth of enrichment (the number of germline-reverted Abs with enriched binding for each point mutation). If enriched, the eOD-GT7 amino acid residue is indicated by a cross. (C) Sequence logos depicting amino acids at each of 16 positions in the combinatorial library (top), the sequences selected from the combinatorial library for improved binding to germline-reverted VRC01-class bnAbs (middle), and the final sequence of eOD-GT8 (bottom). Abbreviations: A, Ala; C, Cys; D, Asp; E, Glu; F, Phe; G, Gly; H, His; I, Ile; K, Lys; L, Leu; M, Met; N, Asn; P, Pro; Q, Gln; R, Arg; T, Thr; V, Val; W, Trp; Y, Tyr. (D) Surface plasmon resonance (SPR) dissociation constants measured for both germline-reverted and mature VRC01-class bnAbs against eOD-GT6 and eOD-GT8. Solid blue lines show geometric mean measured over all the data, using the value K D = 100 mM for samples with K D > 100 mM; dashed blue lines show geometric means computed for the eight germline-reverted Abs or 12 bnAbs for which K D s < 100 mM could be measured for both eOD-GT6 and eOD-GT8. The lowermost dotted line signifies the limit of detection for our SPR instrument (16 pM); K D s below this value were measured by KinExa. 590 (geometric mean K D = 5.8 nM for the panel), most likely due to the naïve CDR3 loops in the former as opposed to the affinity-matured CDR3 loops in the latter. The VRC01-class naïve B cell affinities are in the range expected to allow a multivalent eOD-GT8 immunogen, such as eOD-GT8 60mer (2, 9) , to activate B cells and initiate germinal centers (21, 22) . Our data also suggest that eOD-GT8 has promise to produce VRC01-class memory even given competition from non-VRC01-class B cells, as eOD-GT8 exhibited a high degree of CD4bs immunofocusing (Fig. 2C ) and VRC01-class precursors had an affinity advantage (factor of ≥3) over non-VRC01-class CD4bs epitope-binding precursors (Fig. 2L) . The frequencies and eOD-GT8 affinities of bona fide VRC01-class precursors isolated here warrant human immunization studies with eOD-GT8 60mer nanoparticles.
Only 2 of 20 tested VRC01-class precursors had detectable affinity for eOD-GT6 (Fig. 2L) . Equilibrium binding K D values were 36 mM and 69 mM, and these Abs had two of the highest affinities for eOD-GT8 at 506 nM and 258 nM, respectively (table S4) . These data, combined with the failure of eOD-GT6 probe B cell screens to isolate VRC01-class precursors, suggest that the engineered breadth and affinity improvements in eOD-GT8 represent a major advance toward practical utility in human vaccination.
We sought to confirm that the isolated VRC01-class precursors engage the CD4bs in the same structural binding mode as VRC01-class bnAbs (6, 17, (23) (24) (25) and germline-reverted VRC01 (9) . We solved the crystal structure of isolated precursor VRC01c-HuGL2 (eOD-GT8 K D = 368 nM) SCIENCE sciencemag.org 25 in complex with eOD-GT8 in two crystal forms (I222, 2.16 Å, and C2, 2.44 Å; table S5). Comparison of this structure with the complex of core-gp120 bound to VRC01 [PDB ID: 3NGB (6)] shows the same binding mode (Fig. 3A ), including specific H-CDR2 and L-CDR3 conformations ( Fig. 3B ) (26) that together account for more than 67.2% of the Fv domain buried surface area ( Fig. 3C and table S6 ). When interface residues of eOD-GT8 and core-gp120 are aligned, V H and V L of VRC01c-HuGL2 and VRC01 have high similarity (Ca RMSD 0.7 Å; Fig. 3A and fig. S9 ). These structural observations confirm VRC01c-HuGL2 as a bona fide VRC01-class precursor and support the conclusion that all of the eOD-GT8-specific naïve B cells using VH1-2 and a 5-amino acid L-CDR3 are bona fide VRC01-class precursors.
Comparison of the eOD-GT8-VRC01c-HuGL2 structure with a 1.82 Å unliganded VRC01c-HuGL2 structure shows that the important H-CDR2 and L-CDR3 loops are preconfigured in the unbound state and do not require any conformational changes for engagement with gp120 CD4bs (Fig.  3D) , heightening the appeal of VRC01-class germline targeting. A 2.9 Å unliganded structure of eOD-GT8 (Fig. 3E and fig. S10 ) demonstrates faithful mimicry of the VRC01-class antibodybound conformation (27) , thus helping to explain the increased affinity of eOD-GT8 for true VRC01-class bnAb precursors. The interaction of the naïve human B cell repertoire with vaccine antigens has not been characterized previously. Given the vast immunoglobulin sequence space, direct probing of the human naïve B cell repertoire was a critical test of the physiologically relevant binding potential of the germline-targeting immunogen. The antibody sequence features, binding affinities, and high structural similarity of the eOD-GT8-specific naïve B cell-derived antibodies to VRC01 all demonstrate the power of germline-targeting design when combined with human B cell probing. Similar F F As tumors grow, they acquire mutations, some of which create neoantigens that influence the response of patients to immune checkpoint inhibitors. We explored the impact of neoantigen intratumor heterogeneity (ITH) on antitumor immunity. Through integrated analysis of ITH and neoantigen burden, we demonstrate a relationship between clonal neoantigen burden and overall survival in primary lung adenocarcinomas. CD8 + tumor-infiltrating lymphocytes reactive to clonal neoantigens were identified in early-stage non-small cell lung cancer and expressed high levels of PD-1. Sensitivity to PD-1 and CTLA-4 blockade in patients with advanced NSCLC and melanoma was enhanced in tumors enriched for clonal neoantigens. T cells recognizing clonal neoantigens were detectable in patients with durable clinical benefit. Cytotoxic chemotherapy-induced subclonal neoantigens, contributing to an increased mutational load, were enriched in certain poor responders. These data suggest that neoantigen heterogeneity may influence immune surveillance and support therapeutic developments targeting clonal neoantigens. R ecent studies have highlighted the relevance of tumor neoantigens in the recognition of cancer cells by the immune system (1-4), prompting a renewed interested in personalized vaccines and cell therapies that target cancer mutations (5, 6) . However, although genomic data are revealing the extent of genetic heterogeneity within single tumors (7), the influence of intratumor heterogeneity (ITH) upon the neoantigen landscape and sensitivity to immune modulation is unclear.
To explore neoantigen heterogeneity and its influence on antitumor immunity in earlystage non-small cell lung cancer (NSCLC), we applied a bioinformatics pipeline to seven primary NSCLCs subjected to multiregion sequence analysis (table S1) (8, 9) . In total, 2860 putative neoantigens were predicted across the cohort, with a median of 326 neoantigens predicted per tumor (range of 80 to 741) (Fig. 1A) . Neoantigen heterogeneity varied considerably, with an average of 44% neoantigens found
